Provided by Tiger Trade Technology Pte. Ltd.

Annovis Bio, Inc.

2.37
-0.1150-4.64%
Volume:117.72K
Turnover:284.64K
Market Cap:62.68M
PE:-1.64
High:2.47
Open:2.44
Low:2.35
Close:2.48
52wk High:5.50
52wk Low:1.11
Shares:26.50M
Float Shares:23.22M
Volume Ratio:1.11
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4419
EPS(LYR):-2.3061
ROE:-246.14%
ROA:-105.88%
PB:4.76
PE(LYR):-1.03

Loading ...

Company Profile

Company Name:
Annovis Bio, Inc.
Exchange:
NYSE
Establishment Date:
2008
Employees:
12
Office Location:
101 Lindenwood Drive,Suite 225,Malvern,Pennsylvania,United States
Zip Code:
19355
Fax:
- -
Introduction:
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Directors

Name
Position
Maria Maccecchini
Founder,President,Chief Executive Officer and Director
Michael Hoffman
Chairman of the Board
Claudine Bruck
Director
Mark White
Director
Reid McCarthy
Director

Shareholders

Name
Position
Maria Maccecchini
Founder,President,Chief Executive Officer and Director
Mark Guerin
Chief Financial Officer